Great West Life Assurance Co. Can increased its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 0.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 28,088 shares of the medical research company’s stock after buying an additional 66 shares during the period. Great West Life Assurance Co. Can’s holdings in PerkinElmer were worth $1,913,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in PerkinElmer by 1.8% in the first quarter. Vanguard Group Inc. now owns 10,612,667 shares of the medical research company’s stock worth $616,171,000 after buying an additional 184,749 shares during the last quarter. BlackRock Inc. raised its position in shares of PerkinElmer by 4,652.8% in the first quarter. BlackRock Inc. now owns 5,787,627 shares of the medical research company’s stock worth $336,029,000 after buying an additional 5,665,854 shares during the period. State Street Corp raised its position in shares of PerkinElmer by 2.2% in the first quarter. State Street Corp now owns 3,875,455 shares of the medical research company’s stock worth $225,011,000 after buying an additional 82,817 shares during the period. Primecap Management Co. CA raised its position in shares of PerkinElmer by 0.7% in the first quarter. Primecap Management Co. CA now owns 3,531,955 shares of the medical research company’s stock worth $205,065,000 after buying an additional 25,825 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of PerkinElmer by 3.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,435,172 shares of the medical research company’s stock worth $199,447,000 after buying an additional 99,801 shares during the period. Institutional investors own 91.47% of the company’s stock.
PerkinElmer, Inc. (NYSE:PKI) opened at 65.35 on Friday. The company’s 50-day moving average price is $66.41 and its 200-day moving average price is $61.60. PerkinElmer, Inc. has a 12-month low of $45.35 and a 12-month high of $70.16. The firm has a market capitalization of $7.20 billion, a price-to-earnings ratio of 19.71 and a beta of 0.75.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.67. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The firm had revenue of $547 million during the quarter, compared to analyst estimates of $554.14 million. During the same period last year, the company posted $0.67 EPS. The business’s quarterly revenue was up 2.0% on a year-over-year basis. Equities analysts expect that PerkinElmer, Inc. will post $2.89 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s dividend payout ratio (DPR) is presently 8.46%.
A number of brokerages have recently commented on PKI. Cowen and Company reissued a “market perform” rating and set a $70.00 price target (up from $61.00) on shares of PerkinElmer in a report on Tuesday, June 20th. Jefferies Group LLC reissued a “hold” rating and set a $49.00 price target on shares of PerkinElmer in a report on Monday, May 15th. Wells Fargo & Company began coverage on PerkinElmer in a report on Thursday, July 13th. They set a “market perform” rating and a $72.00 price target on the stock. Zacks Investment Research lowered PerkinElmer from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, BidaskClub lowered PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $67.00.
In related news, Director Peter Barrett sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $63.22, for a total value of $632,200.00. Following the completion of the sale, the director now directly owns 29,200 shares of the company’s stock, valued at approximately $1,846,024. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Andrew Okun sold 4,358 shares of the business’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $65.00, for a total value of $283,270.00. Following the completion of the sale, the insider now directly owns 16,799 shares of the company’s stock, valued at $1,091,935. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
